May 25, 2023 – For patients undergoing total knee arthroplasty (TKA), a combination of intravenous and periarticular corticosteroids does not improve pain control – but, may improve key indicators of functional recovery in the days after surgery, reports a trial in The Journal of Bone & Joint Surgery. The journal is published in the Lippincott portfolio in partnership with Wolters Kluwer.
Intravenous (IV) plus periarticular (PA) steroids “yielded more significant improvements in the rehabilitation parameters,” such as knee movement and walking distance, according to the report by TCW Chan, MBBS, of Queen Mary Hospital, Hong Kong, and colleagues. “Thus, there was more robust evidence that corticosteroids enhanced functional recovery in the patients who received both PA and IV corticosteroids than in those who received intravenous corticosteroids only.”
Trial compares two routes of corticosteroid administration for TKA
TKA is a widely performed and cost-effective procedure, but many patients experience substantial postoperative pain. Previous studies have reported effective pain relief and improved mobilization after TKA with either IV or PA corticosteroid administration.
Chan and colleagues aimed to assess whether a combination of IV and PA corticosteroids could provide further improvement. In the new study, 178 patients undergoing initial TKA were randomly assigned to receive IV, PA, or IV plus PA corticosteroids. A fourth group received inactive placebo injections. All patients received standard opioid medications for pain.
Pain relief and key rehabilitation parameters were compared across groups. Patients and the researchers evaluating outcomes were both blinded to the treatment the patients received.
In first few postoperative days, pain scores at rest and during movement were significantly lower for patients who received IV corticosteroids, with or without PA corticosteroids, as compared with the placebo group. Patients who received PA corticosteroids alone had no reduction in pain scores compared with the placebo.
IV plus PA corticosteroids may enhance functional recovery
The combined use of IV plus PA corticosteroids led to improvement in several physical measures during rehabilitation. At three days, flexion in the operated knee was better for patients who received IV plus PA corticosteroids compared with the placebo.
The IV plus PA corticosteroid group also had greater quadriceps muscle strength and longer walking distances during the first three postoperative days, as well as higher scores on an elderly mobility scale. Some parameters, but not all, were also improved for patients who received IV or PA corticosteroids alone, as compared with the placebo.
Patients who received IV plus PA corticosteroids were also more likely to be discharged home from the hospital, rather than to a rehabilitation facility (67% compared with 38% in the placebo group). Rates of discharge to home were 55% with IV corticosteroids alone and 59% with PA corticosteroids alone.
The study confirms the role of IV corticosteroids in pain management after TKA, with significant reductions in pain scores and morphine use compared with a placebo. Adding PA to IV corticosteroids does not improve postoperative pain control.
However, the combined use of IV plus PA corticosteroids provided greater functional recovery immediately postoperatively. The researchers write, “These improvements in rehabilitation and recovery parameters may have contributed to the higher percentage of patients who were discharged home.”
Dr. Chan and colleagues conclude: “This study provides new insights into pain management in TKA that may enable better functional recovery and rehabilitation after TKA, and thereby advance the ability to perform arthroplasty as an outpatient procedure.”
Read [Pain Relief After Total Knee Arthroplasty with Intravenous and Periarticular Corticosteroid: A Randomized Controlled Trial]
Wolters Kluwer provides trusted clinical technology and evidence-based solutions that engage clinicians, patients, researchers and students in effective decision-making and outcomes across healthcare. We support clinical effectiveness, learning and research, clinical surveillance and compliance, as well as data solutions. For more information about our solutions, visit https://www.wolterskluwer.com/en/health and follow us on LinkedIn and Twitter @WKHealth.
About The Journal of Bone & Joint Surgery
The Journal of Bone & Joint Surgery (JBJS) has been the most valued source of information for orthopaedic surgeons and researchers for over 125 years and is the gold standard in peer-reviewed scientific information in the field. A core journal and essential reading for general as well as specialist orthopaedic surgeons worldwide, The Journal publishes evidence-based research to enhance the quality of care for orthopaedic patients. Standards of excellence and high quality are maintained in everything we do, from the science of the content published to the customer service we provide. JBJS is an independent, non-profit journal.
About Wolters Kluwer
Wolters Kluwer (EURONEXT: WKL) is a global leader in professional information, software solutions, and services for the healthcare, tax and accounting, financial and corporate compliance, legal and regulatory, and corporate performance and ESG sectors. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with specialized technology and services.
Wolters Kluwer reported 2022 annual revenues of €5.5 billion. The group serves customers in over 180 countries, maintains operations in over 40 countries, and employs approximately 20,000 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands.
For more information, visit www.wolterskluwer.com, follow us on LinkedIn, Twitter, Facebook, and YouTube.
Journal of Bone and Joint Surgery